PD3-1-1: ABT-869, a multiple tyrosine kinase inhibitor, has promising activity in patients with non-small cell lung cancer (NSCLC) in a phase I dose escalation study

Ross Soo; Choon-Hua Thng; Norita Sukri; Chiung-Ing Wong; Soo-Chin Lee; Chien-Shing Chen; Rod Humerickhouse; Boon-Cher Goh

doi:10.1097/01.JTO.0000283395.45098.CA

PD3-1-1: ABT-869, a multiple tyrosine kinase inhibitor, has promising activity in patients with non-small cell lung cancer (NSCLC) in a phase I dose escalation study

Ross Soo
, Choon-Hua Thng
, Norita Sukri
, Chiung-Ing Wong
, Soo-Chin Lee
, Chien-Shing Chen
, Rod Humerickhouse
, Boon-Cher Goh

Research output: Contribution to conference › Poster › peer-review

Original language	American English
Pages	S458-S459
DOIs	https://doi.org/10.1097/01.JTO.0000283395.45098.CA
State	Published - Aug 1 2007
Externally published	Yes

Disciplines

Oncology
Internal Medicine
Medicine and Health Sciences

Access to Document

10.1097/01.JTO.0000283395.45098.CALicense: Unspecified

OpenUrl availability

Full text

Cite this

@conference{5a114527a8f949daad21150ed099435d,

title = "PD3-1-1: ABT-869, a multiple tyrosine kinase inhibitor, has promising activity in patients with non-small cell lung cancer (NSCLC) in a phase I dose escalation study",

author = "Ross Soo and Choon-Hua Thng and Norita Sukri and Chiung-Ing Wong and Soo-Chin Lee and Chien-Shing Chen and Rod Humerickhouse and Boon-Cher Goh",

year = "2007",

month = aug,

day = "1",

doi = "10.1097/01.JTO.0000283395.45098.CA",

language = "American English",

pages = "S458--S459",

}

TY - CONF

T1 - PD3-1-1: ABT-869, a multiple tyrosine kinase inhibitor, has promising activity in patients with non-small cell lung cancer (NSCLC) in a phase I dose escalation study

AU - Soo, Ross

AU - Thng, Choon-Hua

AU - Sukri, Norita

AU - Wong, Chiung-Ing

AU - Lee, Soo-Chin

AU - Chen, Chien-Shing

AU - Humerickhouse, Rod

AU - Goh, Boon-Cher

PY - 2007/8/1

Y1 - 2007/8/1

UR - https://www.jto.org/article/S1556-0864(15)34111-3/fulltext

UR - https://www.mendeley.com/catalogue/109d3b20-b600-33cc-9f70-553440537f24/

U2 - 10.1097/01.JTO.0000283395.45098.CA

DO - 10.1097/01.JTO.0000283395.45098.CA

M3 - Poster

SP - S458-S459

ER -

PD3-1-1: ABT-869, a multiple tyrosine kinase inhibitor, has promising activity in patients with non-small cell lung cancer (NSCLC) in a phase I dose escalation study

Disciplines

Access to Document

OpenUrl availability

Other files and links

Cite this